Evidence map›Paper›PMID 32924198›Full record

SynthesisThe oncologist2021

Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.

Maïmouna Mané, Sofian Benkhaled, Tatiana Dragan, Marianne Paesmans, Sylvie Beauvois, Yassine Lalami, Petr Szturz, P Macoumba Gaye, Jan B Vermorken, Dirk Van Gestel

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. SEOM-TTCC clinical guideline in nasopharynx cancer (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Maïmouna Mané *Department of Radiation-Oncology, Dalal Jamm National Hospital Center, Dakar, Senegal.
Sofian Benkhaled *Department of Radiation-Oncology, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.ORCID 0000-0001-7450-9078
Tatiana DraganDepartment of Radiation-Oncology, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
Marianne PaesmansDepartment of Biostatistics Unit-Data centre, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
Sylvie BeauvoisDepartment of Radiation-Oncology, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
Yassine LalamiDepartment of Medical Oncology, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
Petr SzturzDepartment of Medical Oncology, Lausanne University Hospital, Lausanne, Switzerland.
P Macoumba GayeDepartment of Radiation-Oncology, Dalal Jamm National Hospital Center, Dakar, Senegal.
Jan B VermorkenDepartment of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
Dirk Van GestelDepartment of Radiation-Oncology, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, Belgium.
Université Libre de Bruxelles · BECentre Hospitalier National Universitaire de Fann · SNAntwerp University Hospital · BEInstitut Jules Bordet · BEUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeConcurrent chemo radiotherapy (CCRT) has been the standard of care in locally advanced nasopharyngeal carcinoma (LA-NPC) for many years. The role of induction chemotherapy (ICT) has always been controversial. This systematic review and meta-analysis investigates the value of adding ICT to CCRT in LA-NPC. MATERIALS AND

methodsTwo reviewers independently assessed the eligibility of randomized controlled trials (RCTs) comparing ICT followed by CCRT versus CCRT alone, including treatment-naive adult patients with histologically proven nonmetastatic LA-NPC.

resultsEight RCTs with in total 2,384 randomized patients, of whom 69% had N2-N3 disease, were selected. ICT was the allocated treatment in 1,200 patients, of whom 1,161 actually received this. Treatment compliance varied, with a median rate of 92% (range, 86%-100%) of patients receiving all cycles of ICT. The percentage of patients completing radiotherapy was 96% and 95% [(Combined Risk difference(CRD)= 0.004; 95% Confidence Interval (CI) -0.001-0.01; p = 0.14)] in the ICT group and CCRT group, respectively, whereas chemotherapy during radiotherapy could be completed in only 28% of the ICT group versus 61% in the CCRT group (CRD, -0.243; 95% CI, -0.403 to -0.083; p = .003). Grade 3-4 acute toxicity was mostly hematologic during the ICT phase (496 events vs. 191 nonhematologic) and was predominant in the ICT group (1,596 events vs. 1,073 in the CCRT alone group) during the CCRT. Adding ICT to CCRT provided a significant benefit in overall survival (hazard ratio [HR], 0.680; 95% CI, 0.511-0.905; p = .001) and progression-free survival (HR, 0.657; 95% CI, 0.568-0.760; p < .001).

conclusionAlthough ICT followed by CCRT is associated with more acute toxicity and a lower compliance of the chemotherapy during the CCRT phase, this association resulted in a clinically meaningful survival benefit. ICT should be considered as a standard option in patients with LA-NPC, but further study on optimal patient selection for this treatment is warranted. IMPLICATIONS FOR PRACTICE: Locally advanced nasopharyngeal carcinoma (LA-NPC) is a relatively common disease in some parts of the world, with a rather poor prognosis due to its high metastatic potential. The role of induction chemotherapy (ICT) has always been controversial. This meta-analysis found that ICT followed by concurrent chemoradiotherapy (CCRT) in LA-NPC is associated with a significant clinical improvement in both overall survival and progression-free survival compared with CCRT alone. ICT should be considered as a standard option in patients with LA-NPC.

Indexed as

Induction ChemotherapyNasopharyngeal NeoplasmsAdultAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyHumansNasopharyngeal CarcinomaConcurrent chemoradiotherapyInduction chemotherapyMeta-analysisNasopharyngeal carcinomaSystematic review

Identifiers

PMID32924198
PMCPMC7794190
OpenAlexW3084584077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.